Objectives: To study the association between trough ribavirin concentration (C trough ) with sustained virological response (SVR) and haemoglobin (Hb) decrease in HIV/hepatitis C virus (HCV)-co-infected (HIV1/HCV1) patients treated with anti-HCV therapy.
Introduction
Standard treatment for patients chronically infected with hepatitis C virus (HCV) is a combination of pegylated interferon and ribavirin. Comparison among international mega-trials has indirectly suggested, but not demonstrated, that higher doses of ribavirin can be associated with better outcome of anti-HCV treatment. 1, 2 Few studies have directly investigated the relationship between ribavirin plasma concentration and the efficacy of anti-HCV therapy. 3 -6 A challenging pilot study has been conducted on 10 patients with chronic hepatitis C, genotype 1 and high viral load, treated with pegylated interferon a-2a and high dose ribavirin, in order to investigate whether higher plasma concentrations of ribavirin could increase the rate of sustained virological response (SVR). 7 Interestingly, this outcome was achieved by 90% of the patients.
The most common side effect of ribavirin is reversible dose-dependent haemolytic anaemia. In several studies, it was found to be dose and concentration dependent. 3, 4, 8, 9 These findings highlight the importance of determining ribavirin plasma concentration cut-off values associated with relevant decrease in haemoglobin (Hb) levels and with virological response.
In HIV co-infected subjects, the same drugs and the same doses are recommended as in HCV monoinfected patients. 10 -13 In this category of patients, improving the rate of SVR is important, as only 18% of those infected with high level viral load HCV genotype 1 or 4 achieved SVR. Few studies have recently investigated the relationship between plasma concentration of ribavirin, its efficacy and haematological toxicity in HIV/HCV co-infected subjects.
14 -17 A significant correlation with early virological response (EVR) was observed only among patients infected by HCV genotype 1 or 4.
15 Cut-off values of ribavirin plasma or erythrocyte concentration associated with EVR and severe haemolytic anaemia have been reported. 14 -16 The aim of this study was to explore the relationship between trough ribavirin plasma concentrations (C trough ) and the rate of SVR and haematological toxicity in a population of HIV/HCV co-infected patients treated with standard anti-HCV therapy of pegylated interferon and ribavirin.
Patients and methods

Patients
Previously untreated HIVþ/HCVþ subjects attending the outpatient clinic at the Department of Infectious Diseases, University of Turin, were enrolled in this open-label observational prospective study. Inclusion criteria were as follows: age .18 years, positive anti-HIV antibody test, positive anti-HCV antibody test, detectable serum HCV-RNA and T-lymphocyte CD4þ count .200 cells/mm 3 . There were no restrictions on alanine aminotransferase levels, liver histology or concomitant antiretroviral therapy. Patients with other forms of liver disease, active hepatitis A or hepatitis B infection, decompensated liver disease or hepatocellular carcinoma, severe anaemia, severe depression or other psychiatric diseases, significant cardiac or renal disease, seizure disorders or pregnancy were excluded from the study.
The study was approved by the local Ethics Committee and all included patients gave informed consent.
Treatment
Patients were treated with 180 mg of pegylated interferon a-2a or 1.5 mg/kg of pegylated interferon a-2b subcutaneously once weekly, in combination with ribavirin, for 48 weeks, regardless of HCV genotype. Ribavirin was administered twice daily, orally with food as 200 mg capsules/tablets, the daily dose depending on HCV genotype and body weight, as follows: for genoype 2 or 3, a fixed dose of 800 mg daily; and for genotype 1 or 4, 1000 mg daily if ,75 kg or 1200 mg daily if .75 kg.
Monitoring
Following baseline, patients were visited at 2 and 4 weeks and then monthly for the whole treatment period of 48 weeks. 
Measurement of plasma ribavirin concentration
At the same time-point, plasma samples were collected $12 h after the dose administration of ribavirin, just before the following administration (trough value). Sex, age, weight, height, concomitant medications, present dose of interferon and ribavirin, and dose changes were recorded prior to sampling. Patients were also asked about time of last dose intake. Samples were centrifugated at 3000 rpm for 10 min to separate plasma and then stored at 2808C until analysis. Ribavirin concentrations were measured by a previously validated HPLC method. 19 
Study endpoints
Efficacy analysis was performed on patients with a definitive virological outcome of SVR (negative qualitative HCV PCR test at 24 weeks after cessation of the treatment), relapse ( positive qualitative HCV PCR test during the first 24 weeks after the cessation of a successful therapy) and therapeutic failure ( positive qualitative HCV PCR test at 24 weeks of therapy, or ,2 log decrease in HCV-RNA from baseline to week 12). EVR was considered as a negative qualitative HCV-RNA and/or quantitative HCV-RNA decrease .2 log at week 12. In the toxicity analysis, dropouts (for adverse events or loss to follow-up) were considered until the last available observation. Haematological toxicity was considered as a maximum decrease in Hb level .4 g/dL with respect to baseline.
Statistics
The intent to treat (ITT) last observation carried forward method was used to analyse both efficacy and toxicity.
All patients who underwent ribavirin dose reduction or who were administered erythropoietin were excluded from the analysis. Mean ribavirin C trough was calculated as the mean of all available C trough determinations for each subject along the whole study period.
Baseline qualitative characteristics were expressed by their frequency (%), and quantitative features were recorded as median and interquartile range (IQR). x 2 test was used to compare categorical variables. The relationship between potential predictive parameters and EVR, SVR or haematological toxicity was examined by univariate and multivariate linear or logistic regression analysis. Receiver operating characteristic (ROC) curve was used to calculate cut-off values. All P values were two-tailed and differences were considered significant when the P value was less than 0.05. All analyses were performed using SPSS v13.0 (SPSS Inc., Chicago, IL, USA).
Results
Fifty-two patients were included in the study. Their baseline characteristics (demographic and immunovirological) and the treatment schedules (drugs and doses) are summarized in Table 1 . Median (IQR) duration of therapy was 28.8 weeks (13.7 -30.28).
Pharmacokinetic analysis
A total of 223 ribavirin plasma samples were collected and processed. The median (range) number of samples collected for each patient was 3 (1-12). In seven subjects, only one ribavirin C trough determination could be obtained. The weight-adjusted dose of ribavirin administered at baseline was 13 mg/kg (11.7 -14.3). The time-course profile of plasma ribavirin C trough from week 2 to week 24 is shown in Figure 1 . Intra-and interindividual variabilities were 26.8% and 48.15%, respectively. Mean (+SD) ribavirin C trough at month 3 and at the end of therapy was 1637 ng/mL (+580) and 1699 ng/mL (+608), respectively.
Efficacy analysis
Using the ITT analysis, EVR was achieved by 32 (61.5%) patients and SVR by 25 (48.1%). Fourteen (26.9%) had therapy failure. Among the latter, 11 did not reach EVR and the treatment was stopped as they were considered as non-responders; 2 experienced a virological breakthrough after week 12 and 1 relapsed. Thirteen patients (25%) dropped out because of adverse events, mainly correlated to interferon. Four of them dropped out of the study after week 12, and all of these were early virological responders.
Efficacy analyses were performed on the 39 patients with a definitive virological outcome (SVR or non-responders). Demographic and clinical characteristics of this group were not significantly different from the whole study population (data not shown). Genotype 1 or 4 was detected in 20 (51.3%) of these patients. At week 12, a 2 log 10 reduction of HCV-RNA was achieved in 28/39 (71.8%) patients, whereas undetectable HCV-RNA was seen in 24/39 (61.5%) cases. Overall, 28 patients (71.8%) achieved EVR and 25 (64.1%) SVR.
Being infected by HCV genotype 2 or 3 was associated with both EVR (x 2 ¼ 14.555, P , 0.0001) and SVR (x 2 ¼ 10.364, P ¼ 0.002). In fact, EVR and SVR were observed in 19/19 (100%) and 17/19 (89.5%) subjects with genotype 2 or 3, respectively, when compared with 9/20 (45%) and 8/20 (40%) subjects with genotype 1 or 4, respectively. Results of logistic regression analysis are shown in Table 2 . Baseline HCV-RNA was associated with both EVR (P ¼ 0.021) and SVR (P ¼ 0.044) in total population.
Overall, no association between ribavirin C trough and EVR (P ¼ 0.09) or SVR (P ¼ 0.127) was found. However, in patients infected by HCV genotype 1 or 4, logistic regression analysis showed that mean ribavirin C trough was independently associated with EVR (P ¼ 0.036) and SVR (P ¼ 0.046). By ROC analysis, a ribavirin C trough cut-off of 1600 ng/mL was found to be and 7/12 (58.3%) of such subjects with a ribavirin C trough .1600 ng/mL had EVR and SVR, respectively, whereas both these outcomes were observed in only 1/8 (12.5%) subjects with ,1600 ng/mL. As shown in Table 2 , no other factors were associated with virological responses, either in the total population or according to the HCV genotype.
Toxicity analysis
Analyses of haematological toxicity were performed in 52 patients, considering data of dropouts until last observation. Dropout was mainly due to interferon side effects (flu-like syndrome, severe asthenia, thrombocytopenia and psychiatric disorders).
As a consequence of ribavirin administration, Hb levels significantly decreased from baseline to week 2 (P , 0.0001) and from week 2 to week 4 (P ¼ 0.001). After this time-point, Hb continued to decrease from week 4 to week 12 and from week 12 to week 24, but these variations were not statistically significant (P ¼ 0.47 and 0.64, respectively). Variation of Hb level over anti-HCV treatment is shown in Figure 2 . Overall median (range) Hb decrease at last observation before stopping therapy was 21.8 g/dL (26.1; 2.7), and the lowest Hb value reached was 12.17 g/dL (9.7-14.9). In 4/52 (7.7%) patients, Hb level decreased to below 10.0 g/dL. A decrease of .4 g/dL of Hb level was observed in 13 of 52 (25%) cases.
Using linear regression analysis, nadir Hb concentration was correlated with baseline Hb level (R ¼ 20.631, P , 0.0001), ribavirin C trough (R ¼ 20.361, P ¼ 0.009), concomitant highly active antiretroviral therapy (HAART) (R ¼ 20.288, P ¼ 0.039) and baseline platelet count (R ¼ 0.327, P ¼ 0.018). At multivariate analysis, only baseline Hb level (P , 0.0001) and ribavirin C trough (P ¼ 0.02) were confirmed as independent predictors of Hb nadir level. Results of the linear regression analysis are presented in Table 3 .
Using logistic regression analysis, a maximum Hb decrease above 4 g/dL was independently associated with higher baseline Hb level (P ¼ 0.004) and higher ribavirin C trough (P ¼ 0.009), and both these parameters were confirmed to be independent predictors at multivariate analysis (P ¼ 0.012 and 0.043, respectively). Results of the logistic regression analysis are shown in Table 3 .
By using ROC analysis, a cut-off of 2300 ng/mL was found to be associated with an Hb decrease of .4 g/dL (AUROC ¼ 0.751, sensitivity ¼ 46.2% and specificity ¼ 89.7%).
Using this cut-off, 6/10 (60%) subjects with a ribavirin C trough of .2300 ng/mL showed an Hb decrease of .4 g/dL, whereas it was observed in only 7/42 (16.7%) subjects with ,2300 ng/mL (x 2 ¼ 8.08, P ¼ 0.01).
Discussion
Response rates and the frequency of adverse events to anti-HCV combination treatment are probably dependent on the interindividual variability of serum ribavirin concentrations. In this context, measuring ribavirin concentration in plasma could be highly helpful for the management of treated patients. Concerning the possible correlation between ribavirin concentration and antiviral efficacy, data are lacking. 3 According to Jen et al., 20 some optimal target concentrations for ribavirin have been established (10-15 21 and .15 mmol/L 7 ), but these have been tested only in small and difficult-to-treat groups of patients.
Ribavirin's major toxicity is haemolytic anaemia. Sex, age, dose of ribavirin by body weight, pre-treatment platelet count and Hb level were alternatively found to be associated with anaemia or with ribavirin dose reduction due to anaemia. 22 -24 Recently, two studies have addressed ribavirin plasma concentration monitoring as a tool for optimizing anti-HCV therapy in patients with expected poor tolerability. 19, 25 In HIV co-infected patients, a lower rate of response and a higher rate of anaemia and of ribavirin dose reduction were reported when compared with HCV monoinfected subjects. In this setting, looking for ribavirin concentration cut-off values able to predict efficacy and toxicity is particularly challenging.
The only published study found a cut-off of C trough ribavirin of 2700 ng/mL, being able to predict EVR with 70% sensitivity and 49% specificity (P ¼ 0.01).
14 A cut-off value of 2100 ng/mL has been recently proposed by the same authors as able to predict undetectability at week 24, with positive-and negative-predictive values of 87% and 28%, respectively. 15 We previously obtained a cut-off value of 1600 ng/mL, able to predict EVR in genoype 1 HCV-infected patients, 26 and this cut-off has been recently confirmed in a similar population. 27 The present study was therefore the first one to investigate the relationship between ribavirin exposure and SVR. We found a significant correlation between ribavirin C trough and SVR in HCV genoype 1 or 4 infected patients and identified a cut-off value of 1600 ng/mL as the best predictor of both EVR and SVR. Of note, the negative-predictive value of this cut-off was 88.9% and would allow identification of patients with low ribavirin concentration, who would benefit from an increase in dose.
A toxicity cut-off value of 2800 ng/mL has been shown to be able to predict Hb drop of .2 g/dL with 73% sensitivity and 81% specificity (P , 0.001).
14 In our study, we chose a more restrictive definition of haematological toxicity (.4 g/dL Hb decrease), considered as the Hb drop suffered by the higher quartile of our population. We found a cut-off value of plasma ribavirin concentration of 2300 ng/mL, being able to predict this level of haematological toxicity with 46.2% sensitivity and 89.7% specificity.
Lower cut-off values were found in our study when compared with the ones reported in previous studies. 14, 15 It is noteworthy that higher ribavirin doses were used in the latter study (median weight-adjusted dose of 13.9 mg/kg) than in our study (almost 60% of the patients were administered 800 mg/day, with a median weight-adjusted dose of 13 mg/kg), resulting in higher median ribavirin C trough (2300 27 and 2720 14 versus 1700 ng/mL, respectively). This point probably explains the difference in the cut-off values.
Our study has some limitations. First, the analysis of prediction of efficacy and toxicity was performed in two different populations (39 and 52 patients, respectively, the former being included in the latter); for this reason-even if demographic and baseline clinical characteristics were not significantly differentwe could not identify a therapeutical range of ribavirin concentrations, but only two possible cut-off values that can predict the virological response and the haematological toxicity.
Moreover, we could not determine ribavirin C trough at all the pre-established time-points. In seven patients, only one plasma sample was collected (in three subjects, it was obtained at week 2).
Because of the accumulation of ribavirin during the first weeks of therapy (finding confirmed in 10 patients whose ribavirin concentration was measured at all time-points), total exposure to ribavirin could be underestimated.
Finally, excluding patients who required ribavirin dose reduction or who were administered erythropoietin meant that we probably failed to observe the extreme variations of Hb levels. In contrast, in this way, we could consider the mean trough concentration as a good marker of the total exposure to ribavirin, without having to apply complex adjustments for dose modifications. Results represent the coefficient of regression and the P value for each parameter. P values ,0.05 are marked in bold.
In conclusion, we found that a mean ribavirin trough concentration of 1600 ng/mL is associated with higher rates of EVR and SVR in HCV genotype 1 or 4 infected patients and that a mean ribavirin trough concentration of 2300 ng/mL is associated with higher rates of severe haematological toxicity defined as .4 g/dL decrease in the Hb level. Further investigations are required to evaluate their possible use as a clinical tool.
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